Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl

Detalhes bibliográficos
Autor(a) principal: Trivedi, Hemangi Ramesh
Data de Publicação: 2020
Outros Autores: Siriah, Tanvi Mukund, Puranik, Prashant Keshao
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/181623
Resumo: The objective of this study was to determine specific combination of pharmaceutical excipients that lead to formulation of efficient nebivolol hydrochloride SMEDDS and its subsequent formulation into IR-SET (Immediate release- Self emulsifying tablet) which will enhance its solubility and dissolution. Solubility and Pseudo-ternary phase studies were carried out to identify the excipients showing highest solubility and to identify the zone of microemulsion with selected ingredients. Liquid-SMEDDS (L‑SMEDDS) were optimized for Concentration of oil(X1) and Smix(X2) and formulated using a combination of Kollisolv GTA as oil, Tween 80 as surfactant and propylene glycol as co-surfactant which gave smaller droplet size(Y1) 55.98nm , Emulsification time (Y2) 16±1.5 s,% transmittance (Y3) 99.94±0.47%. Neusilin US2 was used as solid carrier for solidification of L-SMEDDS in to Solid-SMEDDS (S-SMEDDS) by adsorption technique. IR-SET of nebivolol were formulated with S-SMEDDS and optimized for the concentration of binder (X1) (PVP K30) and superdisintegrant (X2) (KOLLIDON CL) which showed low Disintegration time (Y1) (92±0.5s) and low Friability(Y2)(0.424±0.03%). Also the DSC and XRD data revealed the molecular state of the drug in S-SMEDDS. The extent of in-vivo drug release and ex-vivo diffusion values from L-SMEDDS and IR-SET was much higher than pure drug and marketed tablet. In conclusion, the results showed potential of SMEDDS to improve solubility and thus the bioavailability.
id USP-31_0bec167ff2ffa7eb0863273957c1da38
oai_identifier_str oai:revistas.usp.br:article/181623
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HClNebivolol hydrochlorideLiquid & Solid SMEDDSFull factorial designNeusilin US2 IR-SETThe objective of this study was to determine specific combination of pharmaceutical excipients that lead to formulation of efficient nebivolol hydrochloride SMEDDS and its subsequent formulation into IR-SET (Immediate release- Self emulsifying tablet) which will enhance its solubility and dissolution. Solubility and Pseudo-ternary phase studies were carried out to identify the excipients showing highest solubility and to identify the zone of microemulsion with selected ingredients. Liquid-SMEDDS (L‑SMEDDS) were optimized for Concentration of oil(X1) and Smix(X2) and formulated using a combination of Kollisolv GTA as oil, Tween 80 as surfactant and propylene glycol as co-surfactant which gave smaller droplet size(Y1) 55.98nm , Emulsification time (Y2) 16±1.5 s,% transmittance (Y3) 99.94±0.47%. Neusilin US2 was used as solid carrier for solidification of L-SMEDDS in to Solid-SMEDDS (S-SMEDDS) by adsorption technique. IR-SET of nebivolol were formulated with S-SMEDDS and optimized for the concentration of binder (X1) (PVP K30) and superdisintegrant (X2) (KOLLIDON CL) which showed low Disintegration time (Y1) (92±0.5s) and low Friability(Y2)(0.424±0.03%). Also the DSC and XRD data revealed the molecular state of the drug in S-SMEDDS. The extent of in-vivo drug release and ex-vivo diffusion values from L-SMEDDS and IR-SET was much higher than pure drug and marketed tablet. In conclusion, the results showed potential of SMEDDS to improve solubility and thus the bioavailability.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2020-12-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/18162310.1590/s2175-97902019000418070Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18070Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18070Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e180702175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/181623/168583Copyright (c) 2020 Brazilian Journal of Pharmaceutical Scienceshttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessTrivedi, Hemangi Ramesh Siriah, Tanvi Mukund Puranik, Prashant Keshao 2021-06-12T19:46:54Zoai:revistas.usp.br:article/181623Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2021-06-12T19:46:54Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
title Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
spellingShingle Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
Trivedi, Hemangi Ramesh
Nebivolol hydrochloride
Liquid & Solid SMEDDS
Full factorial design
Neusilin US2 IR-SET
title_short Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
title_full Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
title_fullStr Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
title_full_unstemmed Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
title_sort Experimental design approach for development of novel microemulsion system and immediate release self microemulsifying tablet of nebivolol HCl
author Trivedi, Hemangi Ramesh
author_facet Trivedi, Hemangi Ramesh
Siriah, Tanvi Mukund
Puranik, Prashant Keshao
author_role author
author2 Siriah, Tanvi Mukund
Puranik, Prashant Keshao
author2_role author
author
dc.contributor.author.fl_str_mv Trivedi, Hemangi Ramesh
Siriah, Tanvi Mukund
Puranik, Prashant Keshao
dc.subject.por.fl_str_mv Nebivolol hydrochloride
Liquid & Solid SMEDDS
Full factorial design
Neusilin US2 IR-SET
topic Nebivolol hydrochloride
Liquid & Solid SMEDDS
Full factorial design
Neusilin US2 IR-SET
description The objective of this study was to determine specific combination of pharmaceutical excipients that lead to formulation of efficient nebivolol hydrochloride SMEDDS and its subsequent formulation into IR-SET (Immediate release- Self emulsifying tablet) which will enhance its solubility and dissolution. Solubility and Pseudo-ternary phase studies were carried out to identify the excipients showing highest solubility and to identify the zone of microemulsion with selected ingredients. Liquid-SMEDDS (L‑SMEDDS) were optimized for Concentration of oil(X1) and Smix(X2) and formulated using a combination of Kollisolv GTA as oil, Tween 80 as surfactant and propylene glycol as co-surfactant which gave smaller droplet size(Y1) 55.98nm , Emulsification time (Y2) 16±1.5 s,% transmittance (Y3) 99.94±0.47%. Neusilin US2 was used as solid carrier for solidification of L-SMEDDS in to Solid-SMEDDS (S-SMEDDS) by adsorption technique. IR-SET of nebivolol were formulated with S-SMEDDS and optimized for the concentration of binder (X1) (PVP K30) and superdisintegrant (X2) (KOLLIDON CL) which showed low Disintegration time (Y1) (92±0.5s) and low Friability(Y2)(0.424±0.03%). Also the DSC and XRD data revealed the molecular state of the drug in S-SMEDDS. The extent of in-vivo drug release and ex-vivo diffusion values from L-SMEDDS and IR-SET was much higher than pure drug and marketed tablet. In conclusion, the results showed potential of SMEDDS to improve solubility and thus the bioavailability.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-09
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181623
10.1590/s2175-97902019000418070
url https://www.revistas.usp.br/bjps/article/view/181623
identifier_str_mv 10.1590/s2175-97902019000418070
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/181623/168583
dc.rights.driver.fl_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Brazilian Journal of Pharmaceutical Sciences
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18070
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18070
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18070
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222915109584896